Meeting
2013 ASCO Annual Meeting
Predictive factors for pathologic complete response (pCR) to trastuzumab(T)-based neoadjuvant chemotherapy in HER2+ breast cancer (BC) women treated in the National Cancer Institute (NCI) of Mexico.
Authors
Erika Sifuentes
Instituto Nacional de Cancerología, Mexico City, Mexico
Erika Sifuentes , Yanin Chavarri Guerra , F. Berenice Baez-Revueltas , Enrique Soto-Perez-de-Celis , Fernando Lara-Medina , Santiago Ruano , Cynthia Mayte Villarreal-Garza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 31, 2013 (suppl; abstr 634)
DOI
10.1200/jco.2013.31.15_suppl.634
Abstract #
634
Poster Bd #
13A
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Magnetic resonance imaging (MRI) evaluation of pathologic complete response (pCR) in different breast cancer subtypes after neoadjuvant chemotherapy (NAC).
First Author: Lucia Gonzalez-Cortijo
Poster
2018 ASCO Annual Meeting
A RB-1 loss of function gene-signature (RBsig) as a tool to predict response to neoadjuvant chemotherapy (CT) plus anti-HER2 agents (H): A substudy of the NeoALTTO trial (BIG 1-06).
First Author: Emanuela Risi
Poster
2015 ASCO Annual Meeting
Docetaxel, cyclophosphamide and trastuzumab as neoadjuvant chemotherapy in HER2-positive primary breast cancer.
First Author: Katsuhiko Nakatsukasa
Poster
2015 ASCO Annual Meeting
Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
First Author: Jacques Raphael